Chemerin in Obese Patients with Nonalcoholic Fatty Liver Disease with or without Prediabetes

Authors

  • Vera Karamfilova Clinic of Endocrinology and Metabolic diseases, University Hospital “Alexandrovska”, Department of Internal Medicine, Medical University – Sofia, Bulgaria
  • Iveta Nedeva Clinic of Endocrinology and Metabolic diseases, University Hospital “Alexandrovska”, Department of Internal Medicine, Medical University – Sofia, Bulgaria
  • Yavor Assyov Clinic of Endocrinology and Metabolic diseases, University Hospital “Alexandrovska”, Department of Internal Medicine, Medical University – Sofia, Bulgaria
  • Antoaneta Gateva Clinic of Endocrinology and Metabolic diseases, University Hospital “Alexandrovska”, Department of Internal Medicine, Medical University – Sofia, Bulgaria
  • Tsvetelina Velikova Department of Clinical Immunology, University Hospital Lozenetz, Bulgaria
  • Nikolay Cherkezov Emergency department, University Hospital “St. Anna”, Bulgaria
  • Ludmila Mateva linic of Gastroenterology, University Hospital “St. Ivan Rilski”, Department of Internal Medicine, Medical University – Sofia, Bulgaria
  • Zdravko Kamenov Clinic of Endocrinology and Metabolic diseases, University Hospital “Alexandrovska”, Department of Internal Medicine, Medical University – Sofia, Bulgaria

DOI:

https://doi.org/10.7546/CRABS.2024.01.15

Keywords:

chemerin, prediabetes, nonalcoholic fatty liver disease, obesity

Abstract

Chemerin is one of the recently discovered adipokines closely related with white adipose tissue and insulin resistance (IR) in obesity, type 2 diabetes mellitus (T2DM), and nonalcoholic fatty liver disease (NAFLD), but some of these data remain controversial.

This study evaluated the relationship between serum chemerin levels, prediabetes and other biochemical and clinical parameters in obese patients with NAFLD.

A total of 79 obese NAFLD patients without ($n=41$) and with prediabetes ($$n=38$$) were included. Serum chemerin was measured using ELISA method.

Chemerin correlated with body mass index (BMI) ($$r=0.320$$, $$p<0.01$$), hip circumference ($$r=0.296$$, $$p<0.05$$) and visceral adiposity index (VAI) ($$r=0.297$$, $$p<0.05$$). Chemerin strongly correlated with hepatic steatosis index (HSI) ($$r=0.550$$, $$p<0.01$$).

Chemerin is adipokine, which has a significant, but yet not unequivocal role in the metabolic process related with obesity, insulin resistance and NAFLD. In this study we were not able to find an association of serum chemerin levels and prediabetes. There were correlations with BMI, hip circumference, Visceral adiposity index and Hepatic steatosis index.

Author Biographies

Vera Karamfilova, Clinic of Endocrinology and Metabolic diseases, University Hospital “Alexandrovska”, Department of Internal Medicine, Medical University – Sofia, Bulgaria

Mailing Address:
Clinic of Endocrinology and Metabolic Diseases,
University Hospital “Alexandrovska”,
Department of Internal Medicine,
Medical University – Sofia
1 Georgi Sofiiski St, 1431 Sofia, Bulgaria

E-mail: verakaramfilova@abv.bg

Iveta Nedeva, Clinic of Endocrinology and Metabolic diseases, University Hospital “Alexandrovska”, Department of Internal Medicine, Medical University – Sofia, Bulgaria

Mailing Address:
Clinic of Endocrinology and Metabolic Diseases,
University Hospital “Alexandrovska”,
Department of Internal Medicine,
Medical University – Sofia
1 Georgi Sofiiski St, 1431 Sofia, Bulgaria

E-mail: iveta_nedeva@yahoo.com

Yavor Assyov, Clinic of Endocrinology and Metabolic diseases, University Hospital “Alexandrovska”, Department of Internal Medicine, Medical University – Sofia, Bulgaria

Mailing Address:
Clinic of Endocrinology and Metabolic Diseases,
University Hospital “Alexandrovska”,
Department of Internal Medicine,
Medical University – Sofia
1 Georgi Sofiiski St, 1431 Sofia, Bulgaria

E-mail: yavovian@abv.bg

Antoaneta Gateva, Clinic of Endocrinology and Metabolic diseases, University Hospital “Alexandrovska”, Department of Internal Medicine, Medical University – Sofia, Bulgaria

Mailing Address:
Clinic of Endocrinology and Metabolic Diseases,
University Hospital “Alexandrovska”,
Department of Internal Medicine,
Medical University – Sofia
1 Georgi Sofiiski St, 1431 Sofia, Bulgaria

E-mail: tony_gateva@yahoo.com

Tsvetelina Velikova, Department of Clinical Immunology, University Hospital Lozenetz, Bulgaria

Mailing Address:
Department of Clinical Immunology,
University Hospital Lozenetz
Eliezer Papo St, 1407 Sofia, Bulgaria

E-mail: ts_velikova@abv.bg

Nikolay Cherkezov, Emergency department, University Hospital “St. Anna”, Bulgaria

Mailing Address:
Emergency department,
University Hospital “St. Anna”
1 Dimitar Mollov St, 1709 Sofia, Bulgaria

E-mail: niki_cherkezov@abv.bg

Ludmila Mateva, linic of Gastroenterology, University Hospital “St. Ivan Rilski”, Department of Internal Medicine, Medical University – Sofia, Bulgaria

Mailing Address:
Clinic of Gastroenterology,
University Hospital “St. Ivan Rilski”,
Department of Internal Medicine,
Medical University – Sofia, Bulgaria
15 Akad. Ivan Evstratiev Geshov, 1431 Sofia, Bulgaria

E-mail: lucymateva@yahoo.com

Zdravko Kamenov, Clinic of Endocrinology and Metabolic diseases, University Hospital “Alexandrovska”, Department of Internal Medicine, Medical University – Sofia, Bulgaria

Mailing Address:
Clinic of Endocrinology and Metabolic Diseases,
University Hospital “Alexandrovska”,
Department of Internal Medicine,
Medical University – Sofia
1 Georgi Sofiiski St, 1431 Sofia, Bulgaria

E-mail: zkamenov@hotmail.com

Downloads

Published

29-01-2024

How to Cite

[1]
V. Karamfilova, “Chemerin in Obese Patients with Nonalcoholic Fatty Liver Disease with or without Prediabetes”, C. R. Acad. Bulg. Sci. , vol. 77, no. 1, pp. 127–136, Jan. 2024.

Issue

Section

Medicine